Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival

Scand J Rheumatol. 2019 Jul;48(4):333-335. doi: 10.1080/03009742.2019.1575980. Epub 2019 Mar 5.

Authors

S Tengesdal¹, A P Diamantopoulos², G Myklebust¹

Affiliations

¹ a Department of Rheumatology , Hospital of Southern Norway , Kristiansand , Norway.
² b Department of Rheumatology , Martina Hansen Hospital , Baerum , Norway.

PMID: 30836040
DOI: 10.1080/03009742.2019.1575980

No abstract available

Publication types

Comparative Study
Letter
Observational Study

MeSH terms

Aged
Antirheumatic Agents / administration & dosage
Antirheumatic Agents / adverse effects
Dose-Response Relationship, Drug
Drug Monitoring / methods
Female
Giant Cell Arteritis* / diagnosis
Giant Cell Arteritis* / drug therapy
Giant Cell Arteritis* / epidemiology
Humans
Leflunomide* / administration & dosage
Leflunomide* / adverse effects
Male
Methotrexate* / administration & dosage
Methotrexate* / adverse effects
Norway / epidemiology
Patient Acuity
Prednisolone / administration & dosage
Prednisolone / adverse effects
Remission Induction / methods
Retrospective Studies
Treatment Outcome

Substances

Antirheumatic Agents
Prednisolone
Leflunomide
Methotrexate